NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the 2024 Annual NMD4C Meeting on September 27th in Calgary!

Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date. The project updates were inspiring to hear, and we are excited to see how our collective efforts will continue to advance our network goals over the coming year. The contributions from the attendees to the discussions and planning have set a strong foundation for the next steps for the year ahead, and we look forward to continuing this momentum. A full meeting summary will be made available to network investigators in the coming weeks.

Additional highlights from our meeting included:

Finally, we would like to thank the organizing team of the WCNMC, which took place directly after our annual meeting. The WCNMC conference provided an excellent forum for the neuromuscular community to gather and learn about clinical practice and research updates, and network with colleagues and we are looking forward to attending again in 2026!

2024 NMD4C Annual Meeting

Read next...

06 - 2026 Basic Research Summer School - EN

NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!

From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages. 

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.